Evaluation of platelet functions in patients taking acetylsalicylic acid as a secondary stroke prevention
 
More details
Hide details
1
Katedra i Klinika Neurologii SUM w Zabrzu Kierownik Kliniki: Prof. dr hab. n. med. Krystyna Pierzchała
 
 
Corresponding author
Beata Łabuz-Roszak   

Klinika Neurologii Śląski Uniwersytet Medyczny, ul. 3 Maja 13/15, 41-800 Zabrze, tel. +48 32 370 45 84
 
 
Ann. Acad. Med. Siles. 2010;64:54-63
 
KEYWORDS
ABSTRACT
Background:
In some patients taking acetylsalicylic acid (ASA) regularly no anti-aggregative eff ect is achieved. This phenomenon is called “aspirin resistance”. Until now, there are no unequivocal data concerning frequency and causes of aspirin resistance in patients taking ASA as secondary stroke prevention. The purpose of the study was to examine platelet functions in patients with diagnosed transient ischemic attack (TIA) or ischemic stroke in the acute phase whom ASA was applied.

Material and Methods:
We examined 70 patients with TIA or stroke treated in the Department of Neurology in Zabrze taking 75–150 mg ASA daily (mean age 68.7±11 years). The assessment of platelet function was performed by multiple platelet function analyzer using the method of impedance aggregometry in the whole blood.

Results:
Aspirin resistance was observed in 6 patients (8.6%). We found no correlation between platelet aggregation and dose, age, sex, time of examination, degree of motor incapability, hypertension, coronary disease, atrial fi brillation, old myocardial infarction. However, we observed correlation between presence of aspirin resistance and high LDL-cholesterol, high BMI and statin intake. No correlation was noted with other biochemical parameters and other drugs.

Conclusions:
The applied method allowed to detect phenomenon of aspirin resistance in some patients with stroke, who were taking ASA in the acute phase. The correlation between antiplatelet eff ect of ASA and either some stroke risk factors (high LDL-level and high BMI) or statin therapy was observed. The usage of multiple platelet function analyzer to monitor antiplatelet eff ect of ASA should be further examined.

 
REFERENCES (46)
1.
Jack D.B. One hundret years of aspirin. Lancet 1997; 350: 437-439.
 
2.
Antiplatelet Trialist` Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.
 
3.
Postuła M., Kapłon A. Oporność na kwas acetylosalicylowy i jego kliniczne znaczenie. Kardiologia w praktyce. 2007; 3(3): 144–152.
 
4.
Antithrombotic Trialist` Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
 
5.
Kamińska M., Musiał W.J., Osada J., Dąbrowska M. Problem „oporności” na leki przeciwpłytkowe. Terapia Kardiodiabetologia 2009; 4: 28–33.
 
6.
Cabe D.J.H., Harrison P., Mackie I.J. i wsp. Assessment of the antiplatelet eff ects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005; 16(5): 269–280.
 
7.
Toth O., Calatzis A., Penz S. i wsp. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb. Haemost. 2006; 96: 781– 788.
 
8.
Sibbing D., Braun S., Jawansky S. i wsp. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiplate electrode platelet aggregometry before and after clopidogrel treatment. Thromb. Haemost. 2008; 99: 121–126.
 
9.
Paniccia R., Antonucci E., Maggini N. i wsp. Assessment of platelet function on whole blood by multiplate electrode platelet aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am. J. Clin. Pathol. 2009; 131: 834–842.
 
10.
Calatzis A., Spannagl M., Loreth R. Multiplate platelet function analysis – application and interpretation. V2.0/07.2007. Dynabyte medical, Monachium 2007.
 
11.
Instrukcja obsługi Multiplate. V.060 403PL. Dynabyte medical, Monachium 2007.
 
12.
Bernstein P.L., Jacobson B.F., Connor M.D., Becker P.J. Aspirin resistance in south African Caucasian patients with thrombotic cerebrovascular events. J. Neurol. Sci. 2009; 277(1-2): 80–82.
 
13.
Bennet D., Yan B., Macgregor L. i wsp. A pilot study of resistance to aspirin in stroke patients. J. Clin. Neurosci. 2008; 15(11): 1204–1209.
 
14.
Zimmermann N., Hohlfeld T. Clinical implications of aspirin resistance. Thromb. Haemost. 2008; 100(3): 379–390.
 
15.
Dharmasaroja P. Aspirin non-responders in Thai ischaemic stroke/TIA patients. J. Med. Assoc. Thai. 2008; 91(6): 818–821.
 
16.
Berrouschot J., Schwetlick B., von Twickel G. i wsp. Aspirin resistance in secondary stroke prevention. Acta Neurol. Scand. 2006; 113: 31–35.
 
17.
Seok J.I., Joo I.S., Yoon J.H. i wsp. Can aspirin resistance be clinically predicted in stroke patients? Clin. Neurol. Neurosurg. 2008; 110(2): 110–116.
 
18.
Żytkiewicz M., Giełwanowska L., Wojtasińska E. i wsp. Resistance to acetylsalicylic acid in patients after ischaemic stroke. Pol. Arch. Med. Wewn. 2008; 118(12): 727–732.
 
19.
Postuła M., Tarchalska-Kryńska B., Filipiak K.J. i wsp. Factors responsible for aspirin resistance – can we identify them? Kardiol. Pol. 2010; 68(4): 412–413.
 
20.
Karepov V., Tolpina G., Kuliczkowski W., Serebruany V. Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after fi rst ischaemic stroke. Cerebrovasc. Dis. 2008; 26(3): 272–276.
 
21.
Velik-Salchner C., Maier S., Innerhofer P. i wsp. Poin-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth. Analg. 2008; 107(6): 1798–1806.
 
22.
Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30mg vs 283mg a day) in patients after a transient ischemic attack of minor ischemic stroke. N. Engl. J. Med. 1991; 325: 1261-1266.
 
23.
Awtry E.H., Loscalza J. Aspirin. Circulation 2000; 101; 1026–1218.
 
24.
Schror K. Aspirin and Platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin. Thromb. Hemost. 1997; 23: 349– 356.
 
25.
Łabuz-Roszak B., Pierzchała K., Porosińska A. i wsp. Oporność na kwas acetylosalicylowy stosowany w prewencji wtórnej udaru mózgu. Badanie pilotażowe. Wiad. Lek. 2010; 3: 171–179.
 
26.
Macchi L., Christaens L., Brizard A. i wsp. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb. Res. 2002; 107: 5–49.
 
27.
Alberts M.J., Bergman D.L., Molner E. i wsp. Antiplatelet eff ect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35: 175–178.
 
28.
Gum P.A., Kottke-Marchand K., Poggio E.D. i wsp. Profi le and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 2001; 88: 230-235.
 
29.
Hung J., Lam J.Y.T., Lacoste L. i wsp. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432–2436.
 
30.
Davis J.W., Hartman C.R., Lewis H.D. i wsp. Cigarette smoking induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J. Lab. Clin. Med. 1985; 105: 479–483.
 
31.
Cipollone F., Ciabattoni G., Patrono C. i wsp. Oxidant stress and aspirin-insensitive tromboxane synthesis in severe unstable angina. Circulation 2000; 102: 1007-1013.
 
32.
Porosińska A., Pierzchała K. Koncepcje oporności na aspirynę. Neurol. Neurochirur. Pol. 2006: 40 (4): 313–319.
 
33.
Friend M., Vucenik I., Miller M. Platelet responsiveness to aspirin in patients with hyperlipidemia. BMJ 2003; 326: 82–83.
 
34.
Jastrzębska M., Torbus-Lisiecka B., Pieczul- Mróz J. i wsp. Ocena funkcji płytek krwi i aktywności inhibitora aktywatora plazminogenu w chorobie niedokrwiennej serca w zależności od współistniejącej hiperlipoproteinemii i leczenia aspiryną. Pol. Arch. Med. Wewn. 1997; 98: 510–519.
 
35.
O`Donnell C.J., Larson M.G., Tofl er G.H. i wsp. Genetic and environmental contributions to platelet aggregation. The Framingham Heart Study. Circulation 2001; 103: 3051–3056.
 
36.
Opper C., Clement C., Wesemann W. i wsp. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis 1995; 113(2): 211–217.
 
37.
Karam J.H., Grodsky G.M., Forsham P.H. Excessive insulin response to glucose in obese subjects as measured by immunochemical assays. Diabetes 1963;12:197– 204.
 
38.
Trovati M., Anfossi G.: Infl uence of insulin and of insulin resistance on platelet and and vascular smooth muscle cell function. J. Diabetes Complications 2002; 16: 35–40.
 
39.
Kamińska M., Osada J., Dąbrowska M. i wsp. Ocena przeciwpłytkowego działania aspiryny wśród pacjentów po zawale serca leczonych PCI w obserwacji półrocznej – wyniki wstępne. Pol. Przeg. Kardiol. 2007; 5: 335–341.
 
40.
Catella-Lawson F., Reilly M.P., Kapoor S.C. i wsp. Cyclooksygenase inhibitors and the antiplatelet eff ects of aspirin. N. Engl. J. Med. 2001; 345: 1809–1817.
 
41.
Kurth T., Glynn R.J., Walker A.M. i wsp. Inhibition of clinical benefi ts of aspirin on fi rst myocardial infarction by nonsteroidal anti-infl amatory drugs. Circulation 2003; 108: 1191–1195.
 
42.
Sibbing D., Morath T., Stegherr J. i wsp. Impact of proton pump inhibitors on the antiplatelet eff ects of clopidogrel. Thromb. Haemost. 2009; 101(4): 714–719.
 
43.
Siller-Matula J.M., Spiel A.O., Lang I.M., Kreiner G., Christ G., Jilma B. Eff ects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 2009; 157(1): 148–153.
 
44.
Siller-Matula J.M., Lang I.M., Christ G., Jilma B. Calcium-channel blockers reduce the antiplatelet eff ect of clopidogrel. J. Am. Coll. Cardiol. 2008; 52(19): 1557–1563.
 
45.
Krasopoulos G., Brister S.J., Beattie W.S., Buchanan M.R. Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336 (7637): 195–198.
 
46.
Buchanan M., Verma S. Biological basis and clinical implications of acetylsalicylic acid resistance. Can. J. Cardiol. 2006; 22(2): 149–151.
 
eISSN:1734-025X
Journals System - logo
Scroll to top